Description:

CALGB 40503 ADVERSE EVENT (AE) FORM NCT00601900 Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=24060959-A5E8-3054-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=24060959-A5E8-3054-E044-0003BA3F9857

Keywords:
Versions (4) ▾
  1. 8/26/12
  2. 1/9/15
  3. 1/9/15
  4. 7/8/15
Uploaded on:

July 8, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

CALGB 40503 ADVERSE EVENT (AE) FORM NCT00601900

If data are amended, circle amended items and check the "Yes" box. If submitting by mail, retain a copy for your records.

CALGB clinical trial administrative data
Are data amended
Patient demographics
Adverse event report
Has an Adverse Event Expedited Report been submitted? (with Central Office based on an event reported below)
Expected Adverse Events
CTC AE Attribution Code (^2)
CTC AE Attribution Code (^2)
CTC Adverse Event Short Name

Similar models